Cancer rates among adults under 50 are climbing faster than expected, with colorectal, breast, stomach, pancreatic, and kidney cancers all showing increases. This trend is forcing health systems worldwide to reconsider when screening should begin, but experts warn that expanding screening without clear evidence of benefit could expose millions to unnecessary testing and false alarms .

A 2023 study published in BMJ Oncology estimated that global cancer incidence in people under 50 will jump by more than 30% between 2019 and 2030, with researchers pointing to diet, alcohol consumption, and tobacco use as potential culprits . The shift is already visible in clinical practice. Yoanna Pumpalova, a medical oncologist treating colorectal cancer at Columbia University Irving Medical Center in New York, noted the change firsthand.

"I see it every day. I have way too many patients who are my age, I'm 37, or even younger, and it's horrible. It's more than it was five years ago; there's no question about it," said Pumpalova.

Yoanna Pumpalova, Medical Oncologist at Columbia University Irving Medical Center

In response to rising early-onset cancer rates, several countries have already lowered their screening recommendations. Australia reduced the recommended starting age for colorectal cancer screening from 50 to 45 in 2024, while most Canadian provinces and territories lowered breast cancer screening eligibility from 50 to 40 or 45 . South Korea launched a new national cancer control plan that will make colonoscopy screening available to anyone aged 45 starting in 2028. The United States also shifted course in 2024 when the US Preventive Services Task Force lowered its recommended starting age for routine mammograms from 50 to 40, citing data showing breast cancer rates among women in their 40s had risen by an average of 2% per year between 2015 and 2019 .

Why Are Younger Adults Getting Cancer More Often?

The reasons behind the increase remain unclear, and experts are divided on whether we're actually seeing more cancer or simply detecting it better. Mark Ebell, a primary care epidemiologist at Michigan State University, suspects that improved screening technologies and expanded screening programs are major factors. "Detection of more cancers in younger persons may just be a consequence of more sensitive and widely used imaging rather than a real increase in incidence," Ebell explained .

However, other researchers argue that screening alone cannot account for the trend. Data from the Australian Institute of Health and Welfare show that colorectal cancers diagnosed in people under 40, a group that would not have been routinely screened, rose from 2.2% of all colorectal cancers in 2000 to around 7.2% in 2025 . This suggests something beyond detection bias is at play.

What Are the Risks of Expanding Cancer Screening to Younger Ages?

While lowering screening ages sounds protective, experts caution that broader screening comes with real harms. About 10% of mammograms performed in the United States between 2005 and 2017 produced false-positive results that led to additional imaging or biopsy, creating anxiety and unnecessary procedures . Colonoscopies, while generally safe, can cause bowel perforations that require emergency surgery, though this remains rare .

Robert Smith, a cancer epidemiologist at the American Cancer Society, emphasized the complexity of the decision.

"There really does need to be a certain prevalence of cancer in the population to justify inviting asymptomatic individuals to undergo screening," said Smith.

Robert Smith, Cancer Epidemiologist at American Cancer Society

Smith also noted that younger women face a particular challenge: dense breast tissue makes it harder for imaging equipment to detect cancer in women in their 30s and early 40s. After menopause, that dense tissue gradually becomes fat tissue, which is easier to image .

Some researchers worry that screening decisions are being made without sufficient evidence. Barron Lerner, a physician and medical historian at New York University School of Medicine, cautioned that the push to lower screening ages may be premature.

"It's a teachable moment for the public about screening. While there is an assumption that screening should find every case of cancer at its earliest stage, achieving this would require expanding testing in ways that would cause unacceptable levels of harm," said Lerner.

Barron Lerner, Physician and Medical Historian at New York University School of Medicine

How Are Doctors Moving Toward Personalized Screening?

Rather than applying a one-size-fits-all approach, some researchers advocate for risk-based screening tailored to individual circumstances. A randomized clinical trial involving more than 28,000 women in the United States found that when mammography frequency is adjusted based on individual risk profile, some women undergo screening less often than they would under routine annual schedules .

Sanjay Shete, a population health scientist at MD Anderson Cancer Center in Houston, Texas, is exploring how genetic risk factors could replace age as the primary screening criterion.

"Below a certain age group, I think we should start looking into more risk-based screening as opposed to simply age-based screening. There are several calculators now coming up, which show that maybe one person is, say, 35, but their risk is the same as a 55-year-old because they have strong family history and they have some other risk factors," said Shete.

Sanjay Shete, Population Health Scientist at MD Anderson Cancer Center

Researchers are also investigating polygenic risk scores, which estimate the combined effect of many gene variations in a patient. A recent study found that a polygenic risk score was better than the standard prostate-specific antigen (PSA) blood test in identifying men who benefitted from prostate cancer screening using magnetic resonance imaging .

What Role Could Multi-Cancer Detection Tests Play?

A potentially transformative approach involves multi-cancer early detection (MCED) tests that can identify multiple cancer types from a single blood draw. These tests analyze abnormal DNA, proteins, and other markers in the blood to detect cancers before symptoms appear . The Galleri test, one such MCED tool, can detect more than 50 types of cancer and has demonstrated the ability to increase cancer detection seven-fold when added to standard screening for breast, cervical, colorectal, and lung cancers .

To expand access to multi-cancer detection, GRAIL announced in 2026 that it would integrate the Galleri test into the Epic electronic health record (EHR) platform, one of the nation's most widely used systems. This integration will allow approximately 450 health systems to order the test directly during patient visits, with results and follow-up managed seamlessly within existing clinical workflows . Broad availability through this integration is expected by the end of 2026 .

Philip Oravetz, Chief Population Health Officer at Ochsner Health, explained the potential impact of embedding such technology into routine care.

"Integrating Galleri directly into Epic enables us to incorporate multi-cancer early detection into routine clinical care in a seamless way for both providers and patients. By embedding Galleri within our existing EHR infrastructure, we reduce administrative burden, support appropriate patient identification, and streamline ordering within established workflows," said Oravetz.

Philip Oravetz, Chief Population Health Officer at Ochsner Health

However, the Galleri test is recommended for adults with elevated cancer risk, such as those aged 50 or older, and should be used in addition to, not instead of, routine cancer screening tests . The test does not detect all cancers, and false positives can occur, requiring confirmatory diagnostic evaluation through imaging or other established medical procedures .

Key Takeaways for Patients and Families

• Rising Early-Onset Cancer: Colorectal, breast, stomach, pancreatic, and kidney cancers are increasing in people under 50, with global incidence projected to rise more than 30% between 2019 and 2030.
• Screening Age Changes: Multiple countries have lowered recommended screening ages, including Australia (colorectal from 50 to 45), Canada (breast from 50 to 40-45), and the United States (breast from 50 to 40).
• Balancing Benefits and Harms: Expanded screening can lead to false positives, unnecessary biopsies, and rare but serious complications like bowel perforation during colonoscopy.
• Risk-Based Approach: Personalized screening based on individual risk factors, family history, and genetic markers may be more effective than age-based screening alone.
• Multi-Cancer Detection: New blood tests like Galleri can detect more than 50 cancer types and are being integrated into major health systems to improve early detection when cancers are most treatable.

The bottom line: while early-onset cancer is a genuine concern, the decision to expand screening requires careful weighing of who benefits most. Rather than screening everyone at a younger age, experts increasingly recommend a personalized approach that considers individual risk factors, family history, and access to advanced detection technologies. Patients should discuss their personal cancer risk with their healthcare provider to determine the most appropriate screening strategy .